Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials

Journal of Clinical Psychiatry

Volumn 65, Issue 2, 2004, Pages 177-186

  Leucht, Stefan ^a,b   Kissling, Werner ^b   McGrath, John ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM CARBONATE; NEUROLEPTIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; EMOTIONAL DISORDER; HUMAN; META ANALYSIS; PATIENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; STATISTICS; TREATMENT OUTCOME;

AFFECTIVE SYMPTOMS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 1842855925     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0206     Document Type: Review

References (51)

1. Wahlbeck K, Cheine M, Essali A. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2002
2. Leucht S, McGrath J, White P, et al. Carbamazepine for schizophrenia: how good is the evidence? J Clin Psychiatry 2002;63:218-224
3. Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2000
4. Prien RF, Point P, Caffey EM, et al. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Arch Gen Psychiatry 1972;27:182-189
5. Shopsin B, Kim SS. A controlled study of lithium versus chlorpromazine in acute schizophrenics. Br J Psychiatry 1971;119:435-440
6. Johnson G, Gershon S, Burdock EI, et al. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971;119:267-276
7. Growe GA. Lithium in chronic schizophrenia. Am J Psychiatry 1979;136:454-455 (Pubitemid 9147457)
8. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981;42:124-128 (Pubitemid 11152740)
9. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-245
10. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993;163(suppl 22):66-78 (Pubitemid 23355892)
11. Wolkowitz OM. Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 1993;5:79-90 (Pubitemid 23210904)
12. Herz MI, Liberman RP, Marder SR, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154:1-63 (Pubitemid 27152428)
13. Lehman AF, Steinwachs DM. At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10 (Pubitemid 28128486)
14. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP): schizophrenia algorithms. J Clin Psychiatry 1999;60:649-657 (Pubitemid 29503644)
15. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000;51:634-638
16. Simhandl C, Meszaros K, Denk E, et al. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia [letter]. Can J Psychiatry 1996;41:317 (Pubitemid 26242438)
17. Schulz SC, Thompson PA, Jacobs M, et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999;60:366-372 (Pubitemid 29289723)
18. Small JG, Klapper MH, Malloy FW, et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003;23:223-228 (Pubitemid 36807788)
19. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry 1997;42:138-143 (Pubitemid 27276077)
20. Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet 1991;337:867-872
21. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996;347:363-366 (Pubitemid 26046104)
22. Clarke M, Oxman AD. Cochrane Collaboration Handbook, version 4.0 (updated July 2000). In: The Cochrane Library. Oxford: Update Software; 2000
23. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:790-812
24. Guy WE. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
25. Boissel JP, Cucherat M, Li W, et al. The problem of therapeutic efficacy indices, 3: comparison of the indices and their use. Therapie 1999;54:405-411
26. Deeks J. Issues in the selection for the meta-analyses of binary data. In: Abstracts of the 8th International Cochrane Colloquium; Oct 25-28, 2000; Cape Town, South Africa
27. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188 (Pubitemid 17189972)
28. Gelenberg AJ, Hopkins HS. Report on efficacy of treatments for bipolar disorder. Psychopharmacol Bull 1993;29:447-456 (Pubitemid 24206389)
29. Bowden CL, Brugger AM, Swann AC, et al, for the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
30. Cochrane Collaboration. Review Manager, 4.1. Oxford: Update Software; 1999
31. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia (protocol). In: The Cochrane Library. Oxford: Update Software; 2002
32. Lerner Y, Mintzer Y. Lithium combined with haloperidol in schizophrenia patients. Br J Psychiatry 1988;153:359-362 (Pubitemid 18228093)
33. Gerlach J, Thorsen K, Munkvad I. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial. Pharmakopsychiatr Neuropsychopharmakol 1975;8:51-56
34. Jus A, Villeneuve A, Gautier J, et al. Deanol, lithium and placebo in the treatment of tardive dyskinesia: a double-blind crossover study. Neuropsychobiology 1978;4:140-149 (Pubitemid 8264573)
35. Simpson GM, Branchey MH, Lee JH, et al. Lithium in tardive dyskinesia. Pharmakopsychiatr Neuropsychopharmakol 1976;9:76-80
36. Garver DL, Hirschowitz J, Fleishmann R, et al. Lithium response and psychoses: a double-blind, placebo-controlled study. Psychiatry Res 1984;12:57-68 (Pubitemid 14111959)
37. Johnstone EC, Crow TJ, Frith CD, et al. The Northwick park "functional" psychosis study: diagnosis and treatment response. Lancet 1988;2:119-125
38. Brockington IF, Kendell JM, Kellet JM, et al. Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 1978;133:162-168 (Pubitemid 8383344)
39. Dube S. Efficacy of lithium in schizophrenia. Indian J Psych 1981;23:193-195 (Pubitemid 14204819)
40. Braden W. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res 1982;7:69-81 (Pubitemid 13249252)
41. Mattes JA. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 1984;19:445-449 (Pubitemid 14130684)
42. Small JG, Kellams JJ. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975;132:1315-1317
43. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder. Arch Gen Psychiatry 1979;36:327-333 (Pubitemid 9125733)
44. Huang LG, Bowden CL. Platelet monoamine oxidase response to lithium treatment in psychiatric patients. J Clin Psychopharmacol 1984;4:326-331 (Pubitemid 15214336)
45. Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment resistant schizophrenic patients. Acta Psychiatr Scand 1991;84:150-154
46. Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double-blind, placebo controlled, parallel design clinical trial. Psychopharmacology (Berl) 1993;111:359-366 (Pubitemid 23165267)
47. Terao T, Oga T, Nozaki S, et al. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study. Acta Psychiatr Scand 1995;92:220-224
48. Hogarty GE, McEvoy JP, Ulrich RF, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995;52:29-41
49. Krawiecka M, Goldberg D, Vaughan MA. Standardized assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977;55:299-308 (Pubitemid 8090438)
50. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane review). In: The Cochrane Library. Oxford: Update Software; 2002
51. LeLorier J, Grégoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-542 (Pubitemid 27352021)